Selecta Biosciences (NASDAQ: SELB)
Q2 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2022-08-11 | ||||||
REV |
Q1 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.110 | 0.080 | 0.1900 | ||||
REV | 13.120M | 33.999M | 20.879M |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Selecta Biosciences (NASDAQ: SELB) through any online brokerage.
Other companies in Selecta Biosciences’s space includes: Macrogenics (NASDAQ:MGNX), Molecular Partners (NASDAQ:MOLN), Innate Pharma (NASDAQ:IPHA), Impel Pharmaceuticals (NASDAQ:IMPL) and Vaxxinity (NASDAQ:VAXX).
The latest price target for Selecta Biosciences (NASDAQ: SELB) was reported by HC Wainwright & Co. on Tuesday, June 21, 2022. The analyst firm set a price target for 4.00 expecting SELB to rise to within 12 months (a possible 196.30% upside). 5 analyst firms have reported ratings in the last year.
The stock price for Selecta Biosciences (NASDAQ: SELB) is $1.35 last updated July 5, 2022, 8:00 PM UTC.
There are no upcoming dividends for Selecta Biosciences.
Selecta Biosciences’s Q2 earnings are confirmed for Thursday, August 11, 2022.
There is no upcoming split for Selecta Biosciences.
Selecta Biosciences is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.